Startup Details

Christopher Locher

CEO

Versatope Therapeutics, Incorporated

Company Name

Versatope Therapeutics, Incorporated

Company Website

http://www.versatope.com

Industry

Biotechnology

Location

UNITED STATES

Developmental Stage

*********

Approx Revenue for current Year

*********

Type of funding

*********

Pre-money Valuation (USD)

*********

Type of offering

*********

Amount of Capital seeking in current round (USD)

*********

Previous capital raised (USD)

*********

Monthly Burn rate (USD)

*********

Company Description

Versatope is developing an innovative universal influenza vaccine (VT-105) that protects animal models against disease and death from diverse pandemic strains. The superiority of VT-105 lies within the technology platform, the potency of the vesicles and genetic engineering to ensure broad-strain protection. We have built upon our success with VT-1... Read more

Product/Service Description

Versatope’s technology also has the potential to leverage its synthetic biology for additional unmet needs in health care including non-viral gene editing, allergy, immunology, oncology, inflammatory bowel disease, topicals, drug delivery, veterinary diseases and more. Multiple discussions with potential partners are ongoing to leverage the technol... Read more

Management Team

Christopher Locher

CEO

Alan Barber

CFO

Kumkum Saxena

VP CMC

Ly Phan

VP Translational Medicine

Maureen Dwyer

Director, Project and Alliance Management

Advisor Team

Jeremy Gowler

BoD Member

Brenda McCabe

BoD Member

Jim Kuo

BoD Member

Carlos Faerman

Director, Structural Biology

Previous Investors

Company Information

Date Company Founded
02/07/2017
Registered Location
Massachusetts
Legal Name
Versatope Therapeutics, Incorporated
Date Company Registered
02/07/2017
Address
, Lowell, Massachusetts
Country
UNITED STATES